Literature DB >> 20147978

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.

A Shimoni, I Hardan, N Shem-Tov, R Yerushalmi, A Nagler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20147978     DOI： 10.1038/leu.2010.12

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  22 in total

1.  Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution.

Authors:  H Nahi; M Remberger; M Machaczka; J Ungerstedt; J Mattson; O Ringden; Katarina Le-Blanc; P Ljungman; H Hägglund
Journal:  Med Oncol       Date:  2012-01-11       Impact factor: 3.064

2.  Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.

Authors:  Erica D Warlick; Marcie Tomblyn; Qing Cao; Todd Defor; Bruce R Blazar; Margaret Macmillan; Michael Verneris; John Wagner; Kathryn Dusenbery; Mukta Aurora; Veronika Bachanova; Claudio Brunstein; Linda Burns; Sarah Cooley; Dan Kaufman; Navneet S Majhail; Brian McClune; Philip McGlave; Jeffrey Miller; Betul Oran; Arne Slungaard; Gregory Vercellotti; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-01       Impact factor: 5.742

3.  Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Authors:  Gheath Alatrash; Kelly M Kidwell; Peter F Thall; Antonio Di Stasi; Julianne Chen; Madhushree Zope; Alyssa K Crain; Richard E Champlin; Uday Popat; Elizabeth J Shpall; Roy B Jones; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2018-12-10       Impact factor: 5.483

4.  Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Authors:  J R Passweg; M Labopin; J Cornelissen; L Volin; G Socié; A Huynh; R Tabrizi; D Wu; C Craddock; N Schaap; J Kuball; P Chevallier; J Y Cahn; D Blaise; A Ghavamzadeh; K Bilger; F Ciceri; C Schmid; S Giebel; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

5.  Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Authors:  R Martino; A Henseler; M van Lint; N Schaap; J Finke; D Beelen; S Vigouroux; E P Alessandrino; G J Mufti; J H Veelken; B Bruno; I Yakoub-Agha; L Volin; J Maertens; R Or; V Leblond; M Rovira; P Kalhs; A F Alvarez; A Vitek; J Sierra; E Wagner; M Robin; T de Witte; N Kröger
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

Review 6.  Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia.

Authors:  Gaurav Goyal; Krishna Gundabolu; Saraschandra Vallabhajosyula; Peter T Silberstein; Vijaya Raj Bhatt
Journal:  Ther Adv Hematol       Date:  2016-04-22

Review 7.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 8.  Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Authors:  Robert J Soiffer; Yi-Bin Chen
Journal:  Blood Adv       Date:  2017-11-28

9.  Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.

Authors:  Erica D Warlick; Regis Peffault de Latour; Ryan Shanley; Marie Robin; Nelli Bejanyan; Alienor Xhaard; Claudio Brunstein; Flore Sicre de Fontbrune; Celalettin Ustun; Daniel J Weisdorf; Gerard Socie
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-06       Impact factor: 5.742

10.  Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.

Authors:  G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.